HIGHLIGHTS
- who: Boris Duchemann and collaborators from the Laboratory of Immunomonitoring in Oncology, Gustave Roussy Cancer Campus, Faculty of Medicine, University Paris-Saclay, Le Kremlin Bicêtre, France have published the research work: Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer, in the Journal: (JOURNAL)
- what: Circulating biomarkers are promising in the field of antitumor immunotherapy, even though they are not yet systematically leveraged in clinical practice.
- how: Clinical data showed that blocking PD-1 or PD-L1 in cancer patients could invigorate T lymphocytes leading to disease control .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.